Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.

Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A.

Br J Clin Pharmacol. 2014 Jun;77(6):998-1010. doi: 10.1111/bcp.12261.

PMID:
24134216
[PubMed - in process]
2.

Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.

Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A.

Br J Clin Pharmacol. 2014 Jun;77(6):986-97. doi: 10.1111/bcp.12260.

PMID:
24134181
[PubMed - in process]
3.

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H.

Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015.

PMID:
20110053
[PubMed - indexed for MEDLINE]
4.

A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.

Venkatakrishnan K, Kramer WG, Synold TW, Goodman DB, Sides E 3rd, Oliva C.

Eur J Clin Pharmacol. 2012 Oct;68(10):1347-55. doi: 10.1007/s00228-012-1262-1. Epub 2012 Mar 30.

PMID:
22460239
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

Roy MJ, Erdman KA, Abeyratne AT, Plumb LC, Lasseter K, Riff DS, Keirns JJ.

Clin Pharmacokinet. 2013 May;52(5):385-95. doi: 10.1007/s40262-013-0047-8.

PMID:
23456393
[PubMed - indexed for MEDLINE]
6.

Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.

Peveling-Oberhag J, Zeuzem S, Yong WP, Kunz T, Paquet T, Bouillaud E, Urva S, Anak O, Sellami D, Kobalava Z.

Clin Ther. 2013 Mar;35(3):215-25. doi: 10.1016/j.clinthera.2013.02.007. Epub 2013 Mar 1.

PMID:
23453404
[PubMed - indexed for MEDLINE]
7.

Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

Schöller-Gyüre M, Kakuda TN, De Smedt G, Woodfall B, Berckmans C, Peeters M, Hoetelmans RM.

Clin Ther. 2010 Feb;32(2):328-37. doi: 10.1016/j.clinthera.2010.02.013.

PMID:
20206790
[PubMed - indexed for MEDLINE]
8.

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.

Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W.

Br J Clin Pharmacol. 2013 Jul;76(1):89-98. doi: 10.1111/bcp.12054. Erratum in: Br J Clin Pharmacol. 2013 Sep;76(3):489.

PMID:
23294275
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.

Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.

PMID:
23208320
[PubMed - indexed for MEDLINE]
10.

Asenapine pharmacokinetics in hepatic and renal impairment.

Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, Gibson GL, de Greef R.

Clin Pharmacokinet. 2011 Jul;50(7):471-81. doi: 10.2165/11590490-000000000-00000.

PMID:
21651314
[PubMed - indexed for MEDLINE]
11.

Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.

Weil A, Martin P, Smith R, Oliver S, Langmuir P, Read J, Molz KH.

Clin Pharmacokinet. 2010 Sep;49(9):607-18. doi: 10.2165/11534330-000000000-00000.

PMID:
20690783
[PubMed - indexed for MEDLINE]
12.

An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.

Baird-Bellaire S, Behrle JA, Parker VD, Patat A, Paul J, Nichols AI.

Clin Ther. 2013 Jun;35(6):782-94. doi: 10.1016/j.clinthera.2013.03.013. Epub 2013 Apr 25.

PMID:
23623756
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics of linagliptin in subjects with hepatic impairment.

Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ.

Br J Clin Pharmacol. 2012 Jul;74(1):75-85. doi: 10.1111/j.1365-2125.2012.04173.x.

PMID:
22242621
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.

Sekar V, Spinosa-Guzman S, De Paepe E, Stevens T, Tomaka F, De Pauw M, Hoetelmans RM.

Clin Pharmacokinet. 2010 May;49(5):343-50. doi: 10.2165/11530690-000000000-00000.

PMID:
20384396
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.

Zhao Q, Iyer GR, Verhaeghe T, Truyen L.

J Clin Pharmacol. 2002 Apr;42(4):428-36.

PMID:
11936568
[PubMed - indexed for MEDLINE]
16.

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.

Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R.

Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7.

PMID:
24906422
[PubMed - in process]
Free PMC Article
17.

Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A.

Pediatr Blood Cancer. 2014 Feb;61(2):238-44. doi: 10.1002/pbc.24686. Epub 2013 Aug 31.

PMID:
23997016
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.

Boinpally R, Alcorn H, Adams MH, Longstreth J, Edwards J.

Clin Drug Investig. 2013 Mar;33(3):199-206. doi: 10.1007/s40261-013-0061-5.

PMID:
23417352
[PubMed - indexed for MEDLINE]
19.

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA.

Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000.

PMID:
22799589
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.

Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J.

Invest Radiol. 2011 Sep;46(9):556-66. doi: 10.1097/RLI.0b013e31821a218a.

PMID:
21623212
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk